索拉费尼布诱导的心血管毒性:令人担忧的原因
Zheng Deng1, Shuang Xiao1, Ying-Ying He1
1Hunan Provincial Key Laboratory of Basic and Clinical Pharmacological Research of Gastrointestinal Cancer, Department of Pharmacy, Institute of Pharmacy and Pharmacology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Chemico-biological interactions
|January 31, 2025
概括
索拉芬尼治疗可能会导致严重的心血管毒性,包括高血压和心力衰竭. 了解这些机制对于开发针对索拉芬尼布的保护性疗法至关重要.
科学领域:
- 心血管药理学心血管药理学
- 在瘤学瘤学.
- 分子毒理学 分子毒理学
背景情况:
- 索拉菲尼布是一种多位氨酸激酶抑制剂,用于治疗肝细胞癌,细胞癌和甲状腺癌.
- 虽然有效延长存活时间,但索拉芬尼会引起显著的心血管毒性,影响患者的生活质量.
- 对于索拉芬尼布诱导的心血管并发症的有效预防和治疗策略有极大需要.
研究的目的:
- 审查索拉芬尼布诱导心血管毒性的发生率和临床表现.
- 总结目前关于这种毒性背后的复杂机制的研究.
- 探索潜在的保护策略,防止索拉费尼布对心血管的不良影响.
主要方法:
- 临床研究和临床前研究的文献综述.
- 关于索拉费尼布心血管不良事件数据的综合.
- 对拟议的分子机制的分析,包括铁灭,死灭和ER压力.
主要成果:
- 在患者中,索拉芬尼与高血压,血栓栓塞和心力衰竭有关.
- 机制包括铁亡,死亡,自,线粒体损伤和内质网膜应激.
- 在临床前研究中,各种药物表现出对索拉费尼布诱导的心脏毒性的保护作用.
结论:
- 索拉费尼布诱导的心血管毒性呈现出各种临床问题,如高血压和心力衰竭.
- 多种细胞通路有助于索拉费尼布的心脏毒性,需要进一步阐明.
- 这一审查为开发有针对性的疗法以减轻索拉芬尼的心血管不良影响提供了基础.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
Exercise and Cardiovascular Response
711
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
711
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K


